XML 22 R7.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2024
Cash flows from operating activities:      
Net income (loss) $ 5,661 $ 10,101  
Adjustments for noncash items:      
Depreciation 4,856 5,086  
Amortization of identifiable intangibles 440 440  
Reduction of right-of-use leased assets 543 529  
Deferred income taxes 429 407  
Accrued pension and post-retirement benefits 39 80  
Stock-based compensation expense 454 472  
Gain on the sale of divested business (565) (9,657) $ 74,900
Changes in assets and liabilities:      
Accounts and other receivables (11,888) (14,931)  
Inventories (19,105) (17,513)  
Income taxes recoverable/payable 436 (71)  
Prepaid expenses and other 6,739 7,174  
Accounts payable and accrued expenses 13,956 12,687  
Lease liability (640) (616)  
Pension and postretirement benefit plan contributions (26) (152)  
Other, net 624 958  
Net cash provided by (used in) operating activities 1,953 (5,006)  
Cash flows from investing activities:      
Capital expenditures (5,141) (2,957)  
Proceeds from the sale of Terphane 565 9,835  
Net cash (used in) provided by investing activities (4,576) 6,878  
Cash flows from financing activities:      
Borrowings 49,950 33,750  
Debt principal payments (38,700) (39,047)  
Net cash provided by (used in) financing activities 11,250 (5,297)  
Effect of exchange rate changes on cash 255 20  
Increase (decrease) in cash and cash equivalents 8,882 (3,405)  
Cash and cash equivalents at beginning of period 6,729 7,062  
Cash and cash equivalents at end of period $ 15,611 $ 3,657 $ 7,062